Thrombotic events in patients with antiplatelet factor 4/heparin antibodies

Heart

Volumn 95, Issue 16, 2009, Pages 1350-1354

  Mattioli, Anna Vittoria ^a   Bonetti, L ^b   Carletti, U ^a   Ambrosio, G ^c   Mattioli, G ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Pavullo Hospital   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d Istituto Nazionale di Ricerche Cardiovascolari   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEPARIN; THROMBOCYTE FACTOR 4; THROMBOCYTE FACTOR 4 ANTIBODY; UNCLASSIFIED DRUG;

AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART SURGERY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

AGED; ANTIBODIES; ANTICOAGULANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HEPARIN; HUMANS; MALE; PLATELET FACTOR 4; THORACIC SURGICAL PROCEDURES; THROMBOCYTOPENIA; THROMBOSIS;

EID: 68049135992     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.160549     Document Type: Article

References (33)

1. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991;10:1-34.
2. Das P, Ziada K, Steinhubl SR, et al. Heparin-induced thrombocytopenia and cardiovascular diseases. Am Heart J 2006;152:19-26.
3. Mattioli AV. Prevalence of anti-PF4/heparin antibodies and the HIT syndrome in cardiovascular medicine. Semin Thromb Hemost 2004;30:291-5
4. Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8
5. Trossaert M, Gaillard A, Commin PL, et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-5.
6. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-6.
7. Selleng S, Selleng K, Wollert HG, et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 2008;6:428-35.
8. Kerendi F, Thourani VH, Puskas JD, et al. Impact of heparin-induced thrombocytopenia on postoperative outcomes after cardiac surgery. Ann Thorac Surg 2007;84:1548-55.
9. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 2003;107:2307-12.
10. Mattioli AV, Bonetti L, Sternieri S, et al. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. It Heart J 2000;1:39-42
11. Fitzmaurice DA, Blann AD, Lip GYH. Bleeding risks of antithrombotic therapy. BMJ 2002;325:828-31
12. Ugolini D, Andreani M, Salani A, et al. Diabetes and bleeding in thoracic surgery. Minerva Chir 2003;58:189-93
13. Serebruany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004;75:40-7
14. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004;2:2133-7
15. Weiss BM, Shumway NM, Howard RS, et al. Optical density values correlate with the clinical probability of heparin induced thrombocytopenia. J Thromb Thrombol 2008;26:243-7
16. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007;5:1666-73.
17. Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-6.
18. Oliveira GBF, Crespo EM, Becker RC, et al, for the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008;168:94-102
19. Overgaard CB, Ivanov J, Seidelin PH, et al. Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention. Am Heart J 2008;156:120-4
20. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000;28:1871-6
21. Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005;128:837-41
22. Trossaert M, Gaillard A, Commin PL, et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-5
23. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133:340S-380S
24. Mattioli AV, Bonetti L, Zennaro M, et al. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Am Heart J 2009;157:589-95
25. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35:1165-76
26. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999;81:625-9
27. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-9
28. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti- PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006;4:281-2
29. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5
30. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2514-8
31. Khairy M, Lasne D, Brohard-Bohn B, et al. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb Haemost 2001;85:1090-6.
32. Pena de la Vega L, Miller RS, Benda MM, et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population based study. Mayo Clin Proc 2005;80:995-1000.
33. Chilver-Stainer L, Lammle B, Alberio L. Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost 2004;91:76-282.